Médicaments et produits sanguins

Avis d'attribution de marché (2002-02-20)
Objet
Métadonnées de l'avis
Type de document: Marché passé

Procédure
Type de procédure: Marché passé
Critères d'attribution
Non défini
Type de soumission: Non défini

Référence
Dates
Date de publication: 2002-03-01 📅
Date de réception: 2002-02-20 📅
Date d'envoi: 2002-02-14 📅
Identifiants
Numéro d'avis (ancien): 33465-2002
Numéro JO-S: 43/2002
Se réfère à l'avis: 106637-2001

Objet
Détails de l'attribution
Marché attribué: Fournisseur(s): Fournisseurs; lots.sous-lots: Abbott France: 24.1; 30.1; 31.1; 419.1; 456.1, 456.2; 465.1, 465.2; 468.1, 468.2; 638.1, 638.2; Aguettant: 7.1; 44.1; 92.1, 92.2; 162.1, 162.2, 162.3; 234.1; 510.1; 513.1, 513.2; 515.1; 516.1; 535.1; 627.1; Alcon: 593.1; 596.1; 597.1; 598.1; 601.1; 601.2; 603.1; 605.1; 606.1; Allergan France SAS: 587.1; Amgen SA: 119.1; 119.2; Asta Médica: 38.1; 48.1, 48.2, 48.3, 48.4, 48.5; 66.1; 107.1, 107.3, 107.4; 130.1, 130.2; 139.1, 139.2, 139.3, 139.4; 268.1, 268.2; 269.1; 272.1; 273.1; 275.1; 276.1; 325.1; Astra Zénéca: 5.1, 5.2, 5.3; 6.1; 8.1; 9.1, 9.2; 11.1, 11.2; 12.1, 12.2, 12.3, 12.4; 13.1, 13.2; 14.1, 14.2, 14.3, 14.4, 14.5, 14.6; 27.1; 28.1; 29.1; 150.1; 153.1, 153.2; 174.1; 176.1; 180.1; 181.1, 181.2; 182.1; 214.1, 214.2; 219.1; 318.1, 318.2; 319.1; 403.1; 454.1; 590.1; 624.1, 624.2; 640.1, 640.2, 640.3; Aventis Pasteur MSD: 476.1, 476.2; 477.1; 478.1; 479.1; 480.1; 481.1; 484.1, 484.2; 671.1; 674.1; Aventis Pharma Distri-Services: 37.1; 54.1; 60.1, 60.2, 60.3, 60.4; 67.1, 67.2, 67.3, 67.4; 68.1; 70.1; 71.1; 77.1; 79.1, 79.2, 79.3; 80.1; 89.1, 89.2, 89.3; 90.1; 91.1, 91.2, 91.3; 99.1; 102.1; 109.1; 112.1, 112.2; 136.1, 136.2; 137.1, 137.2; 141.1; 173.1, 173.2; 175.1; 179.1; 186.1; 197.1, 197.2, 197.3, 197.4; 198.1; 216.1, 216.2, 216.3; 220.1, 220.2; 223.1; 226.2; 227.1; 235.1; 236.1; 289.1; 300.1; 302.1; 304.1; 335.1; 340.1; 346.1; 347.1, 347.2; 348.1, 348.2, 348.3; 356.1, 356.2; 383.1; 384.1; 391.1, 391.2; 394.1; 395.1, 395.2; 414.1, 414.2; 416.1, 416.2; 417.1, 417.2; 421.1; 422.1, 422.2, 422.3, 422.4; 423.1, 423.2; 432.1, 432.2, 432.3; 434.1; 435.1; 437.1; 438.1; 487.1; 488.1; 506.1; 526.1, 526.2, 526.3; 527.1, 527.2; 534.1, 534.2; 542.1, 542.2, 542.3, 542.4; 543.1, 543.2; 545.1, 545.2, 545.3, 545.4; 547.1, 547.2, 547.3, 547.4; 549.1, 549.2, 549.3, 549.4; 552.1, 552.2, 552.3, 552.4; 614.1; 619.1; 621.1, 621.2; 642.1, 642.2; 654.1; 664.1; 676.1; 677.1; 679.1; 694.1; 702.1, 702.2, 702.3; B. Braun Médical: 22.1; Baxter SAS: 21.1; 433.1; 695.2, 695.3, 695.4; 698.1; 704.1, 704.2, 704.3; 707.1, 707.2, 707.3; 712.1, 712.2; 713.1, 713.2, 713.3; Bayer Pharma: 229.1, 229.2, 229.3; 230.1; 231.1; 232.1; 361.1; 413.1, 413.2, 413.3; 703.1, 703.2, 703.3; Beaufour Ipsen Pharma: 209.1; 282.1; 290.1; 321.1; 588.1; Biocodex: 51.1; Boehringer Ingelheim: 187.1; 188.1; 200.1; 201.1; 202.1; 354.1, 354.2, 354.3; 467.1; 615.1; 622.1; 629.1, 629.2; 630.1, 630.2, 630.3; 691.1; Bristol Myers Squibb: 104.1; 117.1; 123.1, 123.2, 123.3, 123.4; 148.1, 148.2; 185.1, 185.2; 211.1, 211.2; 390.1; 443.1, 443.2; 444.1; 461.1, 461.2, 461.3, 461.4, 461.5, 461.6; 470.1, 470.2, 470.3, 470.4, 470.5; Bristol Myers Squibb Pharma SA: 462.1; Byk France SA: 247.1, 247.2; 303.1; 641.1, 641.2, 641.3; Celltech Pharma SA: 265.1; Centre Spécialités Pharmaceutiques: 1.1; 206.1; 238.1, 238.2; 339.1; 442.1; 448.1; 512.1; 514.1; 564.1, 564.2, 564.3, 564.4; 589.1; 600.1, 600.2; 631.1; Chiési SA: 190.1; 496.1; 497.1; Coopération Pharmaceutique Française: 46.1, 46.2; 95.1; 258.1, 258.2; 298.1, 298.2, 298.3; 493.1; 494.1; 611.1; Eisaï SA: 586.1; Entéris: 294.1; Ferring SAS: 280.1; 281.1; 288.1; 313.1; 362.1; Frésénius Hémocare France: 370.1; Fujisawa France: 374.1, 374.2, 374.3; Génopharm: 529.1; Genzyme SA: 502.1; Gifrer Barbezat: 260.1; 262.1; 612.1; Gilead Sciences: 110.1; 445.1; 471.1; Glaxosmithkline: 15.1, 15.2; 16.1, 16.2, 16.3, 16.4; 17.1; 63.1, 63.2, 63.3; 138.1, 138.2; 155.1; 207.1; 250.1; 251.1, 251.2; 320.1; 327.1, 327.2; 328.1; 329.1; 330.1; 331.1, 331.2; 332.1; 333.1; 344.1, 344.2; 364.1, 364.2; 375.1, 375.2, 375.3; 376.1, 376.2, 376.3, 376.4; 377.1, 377.2, 377.3, 377.4; 378.1, 378.2; 379.1; 380.1; 387.1, 387.2, 387.3; 388.1, 388.2, 388.3; 396.1, 396.2; 397.1; 401.1, 401.2; 406.1, 406.2; 458.1; 459.1; 460.1, 460.2, 460.3; 464.1, 464.2; 473.1, 473.2, 473.3, 473.4, 473.5; 474.1; 475.1; 482.1, 482.2; 483.1, 483.2; 540.1, 540.2; 540.3; 578.1, 578.2; 591.1; 618.1; 623.1; 635.1, 635.2, 635.3; 636.1; 637.1; 646.1, 646.2; Imtix Sangstat SAS: 371.1; Isotec SAS: 508.1; Janssen Cilag SA: 32.1, 32.2; 40.1, 40.2, 40.3, 40.4; 64.1, 64.2; 254.1, 254.2; 295.1, 295.2; 296.1, 296.2; 311.1, 311.2; 449.1, 449.2; 530.1; 548.2, 548.3, 548.4, 548.5, 548.6, 546.7, 546.8; 553.1, 553.2, 553.3, 553.4; 683.1; 686.1; LFB: 692.1, 692.2, 692.3; 693.1, 693.2, 693.3; 696.1, 696.2; 700.1; 701.1, 701.2; 705.1, 705.2, 705.3; 708.1; 710.1, 710.2; 711.1, 711.2, 711.3, 711.4; 716.1; 717.1, 717.2; 718.1; 719.1; Lafon: 93.1, 93.2, 93.3; 94.1; 183.1, 183.2; 184.1, 184.2; 322.1; Léo SA: 349.1, 349.2, 349.3; 428.1, 428.2, 428.3; 500.1; 518.1, 518.2, 518.3, 518.4, 518.5; Lilly France: 128.1, 128.2; 157.1; 159.1, 159.2; 161.1; 491.1; 551.1, 551.2, 551.3; 576.1, 576.2; Lipha Santé: 177.1; 178.1; 203.1; 213.1, 213.2; 224.1, 224.2; 228.1, 228.2; 485.1; 486.1, 486.2; 495.1, 495.2; 582.1; 655.1, 655.2, 655.3; Lundbeck SA: 558.1, 558.2, 558.3, 558.4, 558.5, 558.6; 573.1, 573.2; Merck Génériques: 2.1, 2.2; 3.1, 3.2; 4.1; 39.1, 39.2; 72.1, 72.2; 121.1, 121.2, 121.3, 121.4; 270.1; 271.1; 274.1; 343.1; 389.1; 399.1, 399.2; 407.1, 407.2, 407.3, 407.4; 411.1, 411.2; 420.1; 425.1; 426.1; 427.1; 450.1, 450.2; 451.1, 451.2; 546.1, 546.2; 559.1, 559.2, 559.3; 592.1; 672.1; Merck Sharp & Dohme BV: 242.1; 463.1, 463.2; Merck Sharp & Dohme-Chibret: 87.1; 167.1; 212.1, 212.2; 221.1, 221.2; 382.1, 382.2, 382.3; 402.1; 415.1; 507.1; 594.1; 599.1, 599.2, 599.3, 599.4; 608.2; 609.1; 645.1; Norgine Pharma: 307.1; 308.1; 323.1; 324.1; Novartis Pharma SA: 73.1, 73.2; 74.1; 76.1; 118.1; 146.1, 146.2, 146.3; 166.1, 166.2; 192.1; 225.1, 225.2; 283.1, 283.2, 283.3; 284.1, 284.2, 284.3; 365.1; 366.1, 366.2; 367.1, 367.2, 367.3, 367.4, 367.5; 368.1, 368.2, 368.3, 368.4; 436.1; 505.1, 505.2; 522.1, 522.2, 522.3, 522.4; 537.1; 574.1, 574.2, 574.3, 574.4; 628.1; 644.1, 644.2, 644.3; 647.1, 647.2, 647.3; 649.1; 650.1; 651.1; 721.1; Novartis Santé Familiale SA: 96.1; 656.1; Novo Nordisk Pharmaceutique: 490.1; 699.1, 699.2; Octapharma SA: 715.1, 715.2, 715.3, 715.4; Organon SA: 18.1; 19.1, 19.2; 65.1, 65.2, 65.3; 97.1, 97.2, 97.3; 172.1; 299.1; 345.1; 577.1, 577.2, 577.3; Panpharma: 204.1; 385.1, 385.2; 392.1; 393.1; 400.1; 404.1; 405.1, 405.2; 408.1, 408.2, 408.3; 554.1; Pfizer: 25.1; 86.1; 88.1; 165.1; 292.1; 293.1; 305.1; 336.1; 336.2, 336.3, 336.4; 418.1; 446.1, 446.2, 446.3, 446.4; 447.1, 447.2; 489.1; 503.1, 503.2; 524.1; 525.1, 525.2, 525.3, 525.4; 569.1, 569.2, 569.3; 579.1; 626.1; Pharmacia SAS: 20.1; 78.1, 78.2; 81.1; 82.1, 82.2, 82.3, 82.4; 83.1, 83.2, 83.3, 83.4; 108.1, 108.2, 108.3; 115.1, 115.2, 115.3; 129.1, 129.2, 129.3, 129.4, 129.5; 152.1; 317.1; 337.1; 338.1, 338.2, 338.3; 429.1, 429.2; 452.1; 652.1; 680.1; 681.1, 681.2; Pierre Fabre Médicament: 205.1; 245.1; 617.1; Ratiopharma: 248.1, 248.2; 253.1, 253.2; 430.1; Renaudin: 43.1; 45.1, 45.2; 61.1; 75.1; 314.1; 678.1; Roche: 23.1; 26.1, 26.2, 26.3; 85.1; 122.1, 122.2; 131.1, 131.2, 131.3, 131.4, 131.5; 151.1, 151.2; 156.1; 355.1; 369.1; 372.1; 373.1; 398.1, 398.2; 440.1; 441.1, 441.2, 441.3; 455.1, 455.2; 466.1, 466.2, 466.3; 469.1, 469.2; 472.1, 472.2; 521.1, 521.2; 523.1, 523.2, 523.3; 538.1, 538.2, 538.3, 538.4, 538.5; 560.1; 563.1, 563.2, 563.3, 563.4, 563.5; 570.1; 632.1; 669.1, 669.2; 682.1; 684.1, 684.2; 685.1, 685.2, 685.3, 685.4. 685.5, 685.6; Roche Nicholas SA: 259.1, 259.2; 509.1; 519.1; SERB SA: 50.1; Sanofi Synthelabo: 33.1, 33.2; 34.1, 34.2, 34.3, 34.4; 124.1, 124.2; 142.1; 143.1; 147.1, 147.2; 163.1; 164.1; 168.1, 168.2, 168.3; 169.1; 170.1; 171.1; 189.1; 193.1; 194.1, 194.2; 195.1, 195.2; 196.1; 210.1, 210.2; 239.1, 239.2; 241.1; 244.1; 246.1; 278.1; 279.1; 285.1; 315.1; 316.1, 316.2; 334.1; 350.1; 351.1, 351.2; 352.1; 357.1, 357.2; 358.1; 359.1; 363.1; 381.1; 424.1; 431.1, 431.2; 531.1, 531.2, 531.3; 532.1; 533.1; 544.1, 544.2, 544.3, 544.4, 544.5; 555.1; 556.1; 557.1; 562.1, 562.2, 562.3, 562.4, 562.5, 562.6; 566.1; 567.1; 571.1; 572.1; 585.1, 585.2; 625.1; 660.1; 663.1; 665.1; 688.1, 688.2; 690.1; Schéring Plough: 35.1, 35.2; 98.1; 113.1, 113.2; 132.1, 132.2, 132.3, 132.4; 133.1, 133.2, 133.3; 134.1, 134.2, 134.3 134.4, 134.5; 154.1, 154.2, 154.3, 154.4; 208.1, 208.2; 409.1; 410.1, 410.2, 410.3; 457.1; 583.1, 583.2, 583.3; 661.1; Schéring SA: 120.1; 217.1; Servier: 127.1; 199.1; 215.1; 240.1; 243.1; 539.1; 580.1; 620.1; Solvay Pharma: 297.1, 297.2; 301.1; Teva Pharma SA: 103.1, 103.2, 103.3; 105.1; 106.1; 114.1, 114.2, 114.3, 114.4; 116.1, 116.2, 116.3; 140.1, 140.2, 140.3; Thérabel Lucien Pharma: 126.1; UPSA Laboratoires: 41.1, 41.2, 41.3; 42.1, 42.2, 42.3, 42.4, 42.5; 47.1, 47.2, 47.3; 52.1; 53.1; 56.1; 57.1, 57.2, 57.3; 58.1; 59.1; 62.1, 62.2; 69.1; 517.1; 561.1; 633.1; 643.1; Wyeth Lederle: 125.1, 125.2, 125.3; 145.1, 145.2, 145.3; 149.1; 386.1, 386.2; 550.1, 550.2, 550.3, 550.4; 565.1, 565.2; 568.1, 568.2; 581.1, 581.2; 657.1; 720.1, 720.2, 720.3.
Source: OJS 2002/S 043-033465 (2002-02-20)